bortezomib
Showing 1 - 25 of 502
Bortezomib, Glomerulonephritis, MN Trial in Shanghai (Bortezomib)
Recruiting
- Bortezomib
- +5 more
- Bortezomib
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
May 19, 2022
Multiple Myeloma Trial in Rionero in Vulture (Bortezomib, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- Dexamethasone
-
Rionero in Vulture, Potenza, ItalyIrccs Crob
Mar 24, 2022
Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)
Not yet recruiting
- Relapsed/Refractory Immune Thrombocytopenia
- Bortezomib
-
Seoul, Korea, Republic of
- +1 more
Oct 30, 2022
Antibody-mediated Rejection Trial in Tehran (Bortezomib)
Recruiting
- Antibody-mediated Rejection
- Bortezomib
-
Tehran, Iran, Islamic Republic ofSBMU
Jan 27, 2022
Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021
Amyloidosis; Systemic Trial in Beijing (Daratumumab, Bortezomib, Dexamethasone)
Active, not recruiting
- Amyloidosis; Systemic
- Daratumumab
- +2 more
-
Beijing, ChinaPeking Union Medical College Hospital
May 9, 2022
Hematological Malignancy Trial in Detroit (Bortezomib)
Recruiting
- Hematological Malignancy
- Bortezomib
-
Detroit, MichiganHenry Ford hospital
Dec 23, 2021
Solid Tumor, Urethral Cancer Trial in Houston (Bortezomib, Gemcitabine, Doxorubicin)
Active, not recruiting
- Solid Tumor
- Urethral Cancer
- Bortezomib
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 21, 2022
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- Bortezomib
-
Mexico City, MexicoHospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)
Recruiting
- Graft-versus-host Disease
- Cyclophosphamide
- +2 more
-
New York, New YorkNYU Langone Health
Mar 24, 2022
Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)
Recruiting
- Multiple Myeloma
- Bortezomib
- +3 more
-
Chicago, Illinois
- +1 more
Mar 14, 2022
Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
- Bortezomib
- Ruxolitinib
-
Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
Dec 3, 2021
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca Trial run by the National Heart, Lung, and Blood Institute
Completed
- Chronic Myeloid Leukemia (CML)
- +4 more
- Bortezomib
- NK cells
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 7, 2022
Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)
Recruiting
- Newly Diagnosed Multiple Myeloma
- Daratumumab
- +4 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Nov 30, 2021
Plasma Cell Myeloma Trial in Atlanta (Bortezomib, Daratumumab, Dexamethasone)
Recruiting
- Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Dec 16, 2021
Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma Trial in Chicago (Bortezomib, Placebo, Mycophenolate mofetil)
Completed
- Lung Diseases, Interstitial
- +2 more
- Bortezomib
- +2 more
-
Chicago, IllinoisNorthwestern University
Aug 2, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +4 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Aug 5, 2022
Multiple Myeloma Trial in United States (Bortezomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- +2 more
-
Denver, Colorado
- +7 more
Feb 11, 2022
Multiple Myeloma and Plasma Cell Tumor, Neurotoxicity Trial in Duarte (drug, genetic, other, procedure)
Completed
- Multiple Myeloma and Plasma Cell Neoplasm
- Neurotoxicity
- bortezomib
- +9 more
-
Duarte, CaliforniaCity of Hope Medical Center
Aug 17, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +2 more
-
Rochester, MinnesotaMayo Clinic in Rochester
Oct 6, 2021
Multiple Myeloma in Relapse Trial in Boston, Durham (Panobinostat, Dexamethasone, Lenalidomide)
Completed
- Multiple Myeloma in Relapse
- Panobinostat
- +3 more
-
Boston, Massachusetts
- +3 more
Sep 3, 2021